Continuing Medical Education

Anticoagulation: Where have we come from and where are we going? The evidence for and against novel anticoagulants

Greg Symons

Abstract


Warfarin, one of the vitamin K antagonists, has been used since 1940, when it was first approved for the treatment of venous thromboembolism. It is currently the most commonly used anticoagulant, although alternative drugs are available, such as aspirin, clopidogrel and dipyridamol, which have been studied in a number of scenarios. The newest agents available to clinicians are the broad group of novel anticoagulants, such as direct thrombin and direct factor Xa inhibitors, including molecules such as dabigatran, rivaroxaban, apixaban and edoxaban. 

 


Author's affiliations

Greg Symons, Division of Pulmonology, Department of Medicine, Groote Schuur Hospital, Cape Town, South Africa

Full Text

PDF (719KB)

Keywords

vascular disease; novel anticoagulants; continuing medical education

Cite this article

South African Medical Journal 2014;104(2):143-146. DOI:10.7196/SAMJ.7873

Article History

Date submitted: 2013-12-20
Date published: 2014-01-12

Article Views

Abstract views: 2946
Full text views: 1276

Comments on this article

*Read our policy for posting comments here